Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics source : Ir.stockpr.com save search
Cyclo Therapeutics to Present at the 2021 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Published: 2021-06-21 (Crawled : 12:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 0.36%
H: 3.43%
C: -2.73%
disease conference
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Published: 2021-06-17 (Crawled : 12:00) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 3.92%
H: 4.72%
C: -0.38%
phase 3 enroll
Cyclo Therapeutics Announces Launch of New Website
Published: 2021-06-15 (Crawled : 12:00) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: -0.83%
H: 0.56%
C: -4.38%
therapeutics
Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index
Published: 2021-06-14 (Crawled : 12:00) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 2.97%
H: 2.5%
C: -2.61%
therapeutics
Cyclo Therapeutics to Present at the JMP Securities Life Sciences Conference
Published: 2021-06-09 (Crawled : 12:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 1.46%
H: 3.59%
C: -0.11%
life science conference
Cyclo Therapeutics to Participate in the M-Vest Virtual Conference Series: Alzheimer’s Disease Panel
Published: 2021-05-20 (Crawled : 13:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 0.56%
H: 5.76%
C: 5.2%
disease alzheimer conference alzheimer’s alzheimer's disease alzheimer's
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
Published: 2021-05-17 (Crawled : 13:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 4.71%
H: 0.0%
C: -3.96%
financial results results
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
Published: 2021-05-11 (Crawled : 13:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: -5.07%
H: 3.23%
C: 2.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.47%
H: 0.7%
C: 0.52%
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
Published: 2021-04-27 (Crawled : 13:00) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 1.11%
H: 0.83%
C: -0.14%
phase 3 designation
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Published: 2021-03-15 (Crawled : 12:00) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 4.95%
H: 1.24%
C: -1.93%
financial results results
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
Published: 2021-03-12 (Crawled : 13:39) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 11.79%
C: 8.09%
growth conference therapeutics
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
Published: 2021-03-10 (Crawled : 13:58) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: -0.31%
H: 10.42%
C: -6.71%
commercialization therapeutics
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
Published: 2021-03-09 (Crawled : 14:15) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 14.56%
H: 28.18%
C: 7.4%
positive
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Published: 2021-03-04 (Crawled : 14:13) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: -0.49%
H: 3.54%
C: -4.39%
disease treatment phase 1 trial phase 3 phase 2
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
Published: 2021-03-01 (Crawled : 14:14) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 1.8%
H: 4.59%
C: 1.41%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.37%
H: 0.5%
C: -0.33%
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
Published: 2021-02-22 (Crawled : 14:13) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 2.37%
H: 3.89%
C: -8.61%
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
Published: 2021-02-09 (Crawled : 13:14) - ir.stockpr.com
CYTH | $1.21 7.94% 21K
|
Professional, Scientific, and T...
|
| O: 11.76%
H: 41.55%
C: 6.3%
positive
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.